# Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

> **NCT05213637** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 430 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** Expanded Activated Lymphocytes (EAL)
- **PROCEDURE:** transarterial chemoembolization (TACE)

## Key facts

- **NCT ID:** NCT05213637
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-25
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2022-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213637, "Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05213637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*